BioCentury
ARTICLE | Finance

In-licensing gathers steam in China

Why Qiming Ventures backed Zai in one of China's largest biotech rounds

September 8, 2014 7:00 AM UTC

The lead investor in Zai Laboratory Inc.'s recent series A round credits the newco's management team and in-licensing business model for allowing it to secure one of the largest venture rounds in China over the past three years for a therapeutics-focused biotech.

Zai raised $32 million in the round, which was led by Qiming Venture Partners. Kleiner Perkins Caufield & Byers, Sequoia Capital, TF Capital and other, undisclosed investors also participated...